Sulindac sulfide – 10 mg

Brand:
Cayman
CAS:
49627-27-2
Storage:
-20
UN-No:
Non-Hazardous - /

Sulindac (Item No. 10004386) is a non-steroidal anti-inflammatory drug that has an extensive epidemiology documenting reduced human colorectal cancer. In mouse models, sulindac was found not only to inhibit the enzymatic activity of polyp-associated COX-2, but also to downregulate the expression of colonic COX-2 protein to control levels.{4068} Sulindac sulfide is a metabolite of sulindac that has diverse activities.{27308,27307} It inhibits both COX-1 and COX-2 (IC50s = 1.9 and 1.21 µM, respectively), whereas the parent compound, sulindac, is much less effective (IC50 = 58 µM for COX-2 and > 100 µM for COX-1).{8427} Sulindac sulfide also inhibits aldose reductase (IC50 = 279 nM), blocking NADPH-dependent reduction of glucose to sorbitol, and reducing type 2 diabetic complications.{27311} It increases the expression and activity of NAD(P)H quinone oxidoreductase 1.{27309} Sulindac sulfide inhibits colorectal cancer growth both in vitro and in vivo.{27312}  

 

Available on backorder

SKU: 10004387 - 10 mg Category:

Description

A metabolite of sulindac that inhibits both COX-1 and COX-2 (IC50s = 1.9 and 1.21 µM, respectively); also inhibits aldose reductase (IC50 = 279 nM), blocking NADPH-dependent reduction of glucose to sorbitol, and reducing type 2 diabetic complications; inhibits colorectal cancer growth both in vitro and in vivo


Formal name: 5-fluoro-2-methyl-1Z-[[4-(methylthio)phenyl]methylene]-1H-indene-3-acetic acid

Synonyms: 

Molecular weight: 340.4

CAS: 49627-27-2

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|Cyclooxygenases||Product Type|Biochemicals|Xenobiotic Metabolites||Research Area|Cancer||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Immunology & Inflammation|Inflammatory Lipid Mediators|Prostaglandins||Research Area|Lipid Biochemistry|Cyclooxygenase Pathway